The PK and tolerability of paricalcitol after repeated intravenous administration for 2 weeks (total 6 doses at every HD session) are studied in subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal failure.
The purpose of this study is pharmacokinetic \& tolerability.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Enrollment
25
paricalcitol 0.04 mcg/kg three times a week
paricalcitol 0.08 mcg/kg three times a week
paricalcitol 0.16 mcg/kg three times a week
Unnamed facility
Gunma, Japan
Unnamed facility
Hokkaido, Japan
Unnamed facility
Ibaraki, Japan
Unnamed facility
Kagoshima, Japan
Pharmacokinetics
Time frame: 2 weeks
Safety
Time frame: 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
paricalcitol 0.24 mcg/kg three times a week
Unnamed facility
Kumamoto, Japan
Unnamed facility
Nagano, Japan
Unnamed facility
Nagasaki, Japan
Unnamed facility
Saitama, Japan
Unnamed facility
Shizuoka, Japan
Unnamed facility
Tokyo, Japan